• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Enhanced Fortifies Executive Leadership Team & Board of Directors

    11/19/25 7:32:00 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATAI alert in real time by email

    – Co-Founder Maximilian Martin Appointed CEO –

    – Co-Founder Christian Angermayer Appointed Executive Chairman –

    – Jim Murren to join Board of Directors –

    – Company Appoints Sid Banthiya Chief Financial Officer; Promotes Alex Lopez to Chief Brand Officer and Rick Adams to Chief Sporting Officer –

    – Names Chris Jones Chief Communications Officer –

    NEW YORK, Nov. 19, 2025 /PRNewswire/ -- Enhanced, the elite sports competition and performance products company committed to giving athletes and people alike the ability to optimize their health, performance and recovery, today announced that it has fortified its executive leadership team and its board of directors. 

    Enhanced Fortifies Executive Leadership Team & Board of Directors

    Co-Founder Maximilian Martin Appointed Chief Executive Officer

    Maximilian Martin, Co-Founder of Enhanced, has been appointed CEO and assumes all operational leadership duties for the company. Martin is the former CEO and Co-Founder of Bitfield, a bitcoin mining company that was acquired by Northern Data in a €400 million transaction. With Martin's appointment, Founder Dr. Aron D'Souza has transitioned out of the company's day-to-day operations, while remaining a shareholder. 

    "Max and I share an ambitious vision for what Enhanced will become. His track record of taking bold ideas and operationalizing them effectively - combined with his leadership, integrity, and relentless commitment to innovation - make him the ideal choice for CEO of Enhanced," said Dr. Aron D'Souza, Founder of Enhanced. "I'm proud of what we've built together thus far, and I'm excited to help support Max as he carries out our shared vision."

    "Everyone at Enhanced is indebted to Aron for his unparalleled vision, passion and track record of entrepreneurial excellence," said Martin. "His foresight and courage to challenge long-standing sports conventions was integral in setting our company's north star. I look forward to having his continued counsel as we grow and evolve into the future."  

    Co-Founder Christian Angermayer and Jim Murren Join Enhanced Board

    The company is delighted to confirm the appointments of Co-Founder Christian Angermayer and Jim Murren to the Enhanced board of directors. Both join the company with distinguished resumes and career experience relevant to Enhanced's mission. Angermayer joins the board as its Executive Chairman. He is an entrepreneur and financier currently serving as the Founder of Apeiron Investment Group, his family office and investment firm with more than $7 billion in assets under management. Angermayer founded AtaiBeckley (NASDAQ:ATAI) a clinical-stage biopharmaceutical company and currently serves as the company's Chairman. 

    Angermayer is a serial entrepreneur and investor shaping the Next Human Agenda: a future where technology empowers people to live longer, healthier, and happier lives. His family office, Apeiron Investment Group, is driven by a bold optimism in technology's power to enhance human life. Apeiron invests directly in private and public companies, creates and launches new ventures of its own, anchors LP commitments, and takes minority GP stakes in emerging asset managers.

    Murren is an executive with a proven background leading global entertainment companies. He currently serves as Chairman for the Ritz-Carlton Yacht Collection and for the General Commercial Gaming Regulatory Authority (GCGRA) based in the United Arab Emirates (UAE). He enjoyed a distinguished career with MGM Resorts where he retired as Chairman and CEO. Murren has played a critical role in public private partnerships throughout his career including serving on the United States National Infrastructure Advisory Council, the U.S. Travel Association, as well as the leadership board of the Keck School of Medicine at the University of Southern California. He is currently a member of the Board of Trustees for Howard University. Additionally, Murren Co-Founded both Acies Investments, a venture capital firm focused on iGaming, sports betting and technology industries and the Nevada Cancer Institute, a non-profit cancer treatment center.

    Sid Banthiya Named Chief Financial Officer

    A veteran finance executive, Banthiya has over two decades of experience across finance, strategy, and operations. He held the positions of Chief Strategy Officer and Chief Financial Officer at Milk Bar, where he was instrumental in securing multiple successful financing rounds and diversifying the business through a significant retail expansion that broadened its nationwide reach. Banthiya also served as Head of Corporate Development at Blue Apron, spearheading commercial partnerships and managing the company's Initial Public Offering (IPO) process. He has held  roles of increasing responsibility with both UBS and Credit Suisse culminating as a Managing Director. His experience scaling high-growth consumer brands and navigating complex financing landscapes will be crucial as Enhanced further develops its value proposition.

    Alex Lopez & Rick Adams Promoted to Executive Leadership Team

    Enhanced solidified both its brand and sporting operations leadership with the promotions of Alex Lopez and Rick Adams respectively. Lopez will serve as Chief Brand Officer tasked with shaping the organization's global brand positioning and go-to-market strategy, as well as crafting the cultural narratives necessary to propel the Enhanced Games onto the world stage. Lopez spent over two decades at Nike in global brand and marketing leadership roles, including Vice President, Global Men's Creative, where he led some of the most iconic and award-winning campaigns in the company's history. Following his tenure at Nike, he served as President & Global Chief Creative Officer for Interpublic's McCann Worldgroup.

    Adams assumes the role of Chief Sporting Officer with oversight of the company's events and performance operations including delivery of the inaugural Enhanced Games, as well as athlete recruitment and management of the Enhanced Performance Team. Adams has had a distinguished career in high performance athletic operations including a decade-long tenure with the United States Olympic & Paralympic Committee (USOPC) as Chief of Sport Performance and as Chef de Mission for Team USA at both the Beijing and Tokyo Olympic Games. Adams also held the role of Chief Executive Officer, USA Weightlifting and was President and CEO of the East Coast Hockey League.

    Chris Jones Named Chief Communications Officer 

    Chris Jones has been appointed Chief Communications Officer responsible for public affairs, external and internal communications, investor relations, media intelligence and ESG. Jones was most recently Vice President, Communications & Public Affairs for FanDuel where he helped the company establish itself as the market leader in legal online sports betting and iGaming. Prior to FanDuel, Jones was Chief Communications Officer for Interpublic Group's IPG Mediabrands division and Chief Marketing Officer for Sizmek, an advertising-technology company acquired by Amazon.

    "The expansion of our C-suite and our board of directors, signifies our commitment to attracting top talent to power operational excellence as we move toward the inaugural Enhanced Games," said Maximilian Martin, CEO of Enhanced. "Their collective expertise provides us the intellectual capital to build a sustainable business with the Games positioned as an innovator in sport and our product business as a driver of optimized human performance."

    About Enhanced Ltd

    Enhanced, is an elite sports competition and performance products company committed to giving athletes and people alike access to products that optimize their health, performance and recovery. The Enhanced Performance Product line provides consumers access to products, and protocols that optimize health, longevity and vitality. As a premium brand, Enhanced aims to revolutionize and lead the Performance Medicine category. 

    About The Enhanced Games

    The Enhanced Games will champion scientific innovation and integrity in elite sporting competition. Enhanced believes in an objective, evidence-based approach to competition, one that celebrates athletic excellence and unlocks athletes' full potential. The Enhanced Games is not only creating a sporting event that is thrilling for spectators but also a beacon for scientific transparency and athlete welfare. By putting athletes first, it gives them the opportunity to reach their full potential and be compensated accordingly, all while ensuring their safety through rigorous medical supervision and scientific oversight. The inaugural Enhanced Games will take place on May 24, 2026 and will be held at a purpose-built competition complex at Resorts World Las Vegas. The Games will offer unprecedented financial incentives to athletes. 

    For more information about mission of Enhanced please visit www.enhanced.com 

    Contact

    Chris Jones

    Chief Communications Officer, Enhanced Games

    [email protected]

    Cision View original content:https://www.prnewswire.com/news-releases/enhanced-fortifies-executive-leadership-team--board-of-directors-302621028.html

    SOURCE Enhanced

    Get the next $ATAI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATAI

    DatePrice TargetRatingAnalyst
    10/13/2025$12.00Buy
    Needham
    7/29/2025$14.00Outperform
    Oppenheimer
    4/4/2025Buy
    Berenberg
    11/18/2024$15.00 → $10.00Buy
    H.C. Wainwright
    4/3/2024$6.00Hold → Buy
    Maxim Group
    11/1/2022$18.00Buy
    Loop Capital
    11/30/2021$25.00Buy
    Maxim Group
    11/22/2021$40.00 → $50.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $ATAI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Apeiron Investment Group Ltd. bought $19,000,000 worth of shares (8,675,799 units at $2.19) (SEC Form 4)

    4 - ATAI Life Sciences N.V. (0001840904) (Issuer)

    8/18/25 6:00:05 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Apeiron Investment Group Ltd. bought $2,520,000 worth of shares (1,800,000 units at $1.40) (SEC Form 4)

    4 - ATAI Life Sciences N.V. (0001840904) (Issuer)

    3/24/25 5:00:18 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Apeiron Investment Group Ltd. bought $22,755,008 worth of shares (10,835,718 units at $2.10) (SEC Form 4)

    4 - ATAI Life Sciences N.V. (0001840904) (Issuer)

    2/19/25 6:00:05 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Enhanced Fortifies Executive Leadership Team & Board of Directors

    – Co-Founder Maximilian Martin Appointed CEO – – Co-Founder Christian Angermayer Appointed Executive Chairman – – Jim Murren to join Board of Directors – – Company Appoints Sid Banthiya Chief Financial Officer; Promotes Alex Lopez to Chief Brand Officer and Rick Adams to Chief Sporting Officer – – Names Chris Jones Chief Communications Officer – NEW YORK, Nov. 19, 2025 /PRNewswire/ -- Enhanced, the elite sports competition and performance products company committed to giving athletes and people alike the ability to optimize their health, performance and recovery, today announced that it has fortified its executive leadership team and its board of directors.  Enhanced Fortifies Executive Lea

    11/19/25 7:32:00 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AtaiBeckley to Participate in the Jefferies Global Healthcare Conference in London

    NEW YORK and AMSTERDAM, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ:ATAI) ("AtaiBeckley" or "Company"), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced that Srinivas Rao, M.D., Ph.D., Co-Founder and Chief Executive Officer, and Kevin Craig, M.D., Chief Medical Officer, are scheduled to participate in the Jefferies Global Healthcare Conference in London, UK. Details of the company's participation: Format: Fireside chat and 1x1 investor meetingsDate and Time: Fireside chat on Thursday, November 20 at 11:30 A.M. GMT/ 6:30 A.M. ETWebcast link: He

    11/13/25 9:00:00 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AtaiBeckley Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

    BPL-003 (mebufotenin benzoate nasal spray) granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for treatment-resistant depression (TRD) Reported positive topline data from the Phase 2b open-label extension (OLE) study of BPL-003 showing the potential added and sustained antidepressant effects following a second dose in patients with TRD Reported positive open-label Phase 2a data demonstrating improved outcomes with a two-dose induction regimen of BPL-003 in patients with TRDAn End-of-Phase 2 meeting is scheduled with the FDA for BPL-003, anticipate providing guidance on the Phase 3 clinical program in the first quarter of 2026Completed enrollment in the ex

    11/12/25 7:00:00 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham initiated coverage on atai Life Sciences N.V. with a new price target

    Needham initiated coverage of atai Life Sciences N.V. with a rating of Buy and set a new price target of $12.00

    10/13/25 8:51:27 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on atai Life Sciences N.V. with a new price target

    Oppenheimer initiated coverage of atai Life Sciences N.V. with a rating of Outperform and set a new price target of $14.00

    7/29/25 7:39:06 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Berenberg initiated coverage on atai Life Sciences N.V.

    Berenberg initiated coverage of atai Life Sciences N.V. with a rating of Buy

    4/4/25 8:27:07 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Hershberg Robert

    4 - Atai Beckley N.V. (0001840904) (Issuer)

    11/6/25 8:54:40 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Feilding-Mellen Cosmo was granted 7,702,990 shares (SEC Form 4)

    4 - Atai Beckley N.V. (0001840904) (Issuer)

    11/6/25 8:49:06 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Braunstein Scott

    4 - Atai Beckley N.V. (0001840904) (Issuer)

    11/6/25 8:45:17 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    SEC Filings

    View All

    SEC Form 10-Q filed by Atai Beckley N.V

    10-Q - Atai Beckley N.V. (0001840904) (Filer)

    11/12/25 4:11:38 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atai Beckley N.V filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Atai Beckley N.V. (0001840904) (Filer)

    11/12/25 7:19:28 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ATAI Life Sciences N.V. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - ATAI Life Sciences N.V. (0001840904) (Filer)

    11/5/25 8:36:27 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    Leadership Updates

    Live Leadership Updates

    View All

    atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health

    - Srinivas Rao M.D., Ph.D. succeeds as sole Chief Executive Officer- Kevin Craig, M.D. promoted to Chief Medical Officer- Glenn Short, Ph.D. promoted to Chief Scientific Officer- Gerd Kochendoerfer, Ph.D. joins as Chief Operating Officer NEW YORK and BERLIN, Jan. 10, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced key leadership appointments to advance its goal of delivering novel mental health therapeutics. Srinivas Rao M.D., Ph.D., has assumed the role of sole Chief Executive Officer (CEO), joined by the promotions of Kevin Craig, M.D.

    1/10/25 7:00:00 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors

    NEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the appointment of Scott Braunstein, M.D., and Laurent Fischer, M.D., as independent directors of atai's supervisory board ("Board") subject to applicable legal requirements. Scott Braunstein, M.D., is the Chief Executive Officer ("CEO") and Chairman of Marinus Pharmaceuticals, Inc. He is an operating partner at Aisling Capital and serves on the Board of Directors at both Caribou Biosciences, Inc. and Trevena Inc. Previously, Dr. Braunstein was Chief Operati

    5/23/24 7:00:00 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    atai Life Sciences Appoints Anne Johnson as Chief Financial Officer

    NEW YORK and BERLIN, Feb. 06, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company") today announced that Anne Johnson, the Company's interim Chief Financial Officer since October 2023 and Chief Accounting Officer since August 2022, has been named Chief Financial Officer (CFO). Anne succeeds Stephen Bardin as the Company's CFO while Stephen will continue in an advisory role until March 31, 2024 to support the transition. "Anne has been an integral member of our team for over three years and has demonstrated the executive leadership, financial acumen, and track record to lead our financial organization with excellence," said atai Co-founder and Chief Executive Off

    2/6/24 5:00:31 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    Financials

    Live finance-specific insights

    View All

    AtaiBeckley Announces Positive Topline Data from the Phase 2b Open-Label Extension Study of BPL-003, Supporting Safety and Efficacy of a Second Dose in Patients with Treatment-Resistant Depression

    A 12 mg dose of BPL-003 (mebufotenin benzoate nasal spray) administered eight weeks after an initial 12 mg, 8 mg or 0.3 mg dose in the core study of the Phase 2b clinical trial produced additional rapid, clinically meaningful antidepressant effects that were sustained for up to eight weeksPatients who received an active dose of BPL-003 in the core study of the Phase 2b clinical trial (either 8 mg or 12 mg) met response and remission criteria for depression at increased rates after receiving a 12 mg dose in the OLE study, with 63% in response and 48% in remission at Week 8 in the OLE study (Week 16 of the Phase 2b clinical trial)An End-of-Phase 2 meeting has been scheduled with the U.S. Food

    11/10/25 7:00:00 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression

    Study met its primary and all key secondary endpoints, and BPL-003 demonstrated rapid, robust and durable antidepressant effects with a single doseBoth 8 mg and 12 mg single doses of BPL-003 showed statistically significant and clinically meaningful reductions in depressive symptoms at all time points of the study compared to a 0.3 mg low-dose active control out to Week 8BPL-003 was generally well-tolerated at all doses, with 99% of treatment-emergent adverse events being mild or moderate, and no drug-related serious adverse events or suicide-related safety signalsMajority of patients deemed ready for discharge at the 90 minutes post-dose assessment, which suggests BPL-003 could fit within t

    7/1/25 6:00:00 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies

    Strategic combination establishes a market-leading mental health company with a pipeline that includes potentially transformative, rapid-acting psychedelic assets differentiated by their convenient route of administration and short time-in-clinicCombined company will operate under the name atai Beckley with a joint leadership team and Board that leverage the deep psychedelic, drug development and CNS expertise within both organizationsTopline data from the Phase 2b study of BPL-003 in patients with treatment-resistant depression (TRD) is expected in mid-2025 - the largest controlled trial of mebufotenin (5-MeO-DMT) and the first and only controlled trial to investigate mebufotenin in the U.S

    6/2/25 6:00:00 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by ATAI Life Sciences N.V.

    SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)

    9/27/24 7:56:26 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by ATAI Life Sciences N.V. (Amendment)

    SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)

    5/3/24 4:06:02 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by ATAI Life Sciences N.V. (Amendment)

    SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)

    3/12/24 9:30:31 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care